Because RBP functions can be regulated by manipulating the activities of PARP and PARG, PARP1 and PARG inhibitors are potential therapeutics to treat a variety of RBP-related cancer and neurodegenerative diseases. Here, PARP1 is linked to neurodegenerative disease.